Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPYD | Q12882 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL532662 | 1.00 | DPYD (0.31) | DPYD | |
| SCHEMBL11153548 | 0.85 | — | — | |
| SCHEMBL932306 | 0.85 | — | — | |
| SCHEMBL3511404 | 0.81 | KDM5A (0.31) | — | |
| SCHEMBL2827577 | 0.81 | KDM5A (0.31) | — | |
| SCHEMBL7599500 | 0.79 | TDO2 (0.39) | — | |
| SCHEMBL1179741 | 0.79 | CYP2A6 (0.34) | — | |
| SCHEMBL16784516 | 0.77 | MAP3K7 (0.40) | — | |
| SCHEMBL3823196 | 0.77 | DPYD (0.42) | DPYD | |
| SCHEMBL7599692 | 0.76 | TLR8 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | claimed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | claimed |
| EP-3157572-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | claimed |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2016-10-20 | — | — | US | claimed |
| EP-3080289-A2 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2016-10-19 | — | — | EP | claimed |
| WO-2015196130-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | claimed |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2015-10-29 | — | — | US | claimed |
| EP-2931319-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2015-10-21 | — | — | EP | claimed |
| WO-2015089511-A2 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-06-18 | — | — | WO | claimed |
| WO-2014093924-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2014-06-19 | — | — | WO | claimed |
| CN-118955655-A | GE protein antigen variant, preparation method and application thereof | 北京微星生物科技有限公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240165267-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2024-05-23 | — | — | US | disclosed |
| CN-117731769-A | Nucleic acid vaccine for Varicella Zoster Virus (VZV) | 摩登纳特斯有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-20190255194-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX INC (US) | 2019-08-22 | — | — | US | disclosed |
| EP-2931319-B1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-5356882-A | Treating herpes virus | UNIVERSITY OF BIRMINGHAM (GB) | 1994-10-18 | — | — | US | disclosed |
| WO-1994005687-A1 | ANTIVIRAL PYRIMIDINE NUCLEOSIDES | UNIVERSITY OF BIRMINGHAM (GB) | 1994-03-17 | — | — | WO | disclosed |
| WO-1991001326-A1 | ANTIVIRAL PYRIMIDINE NUCLEOSIDES | UNIVERSITY OF BIRMINGHAM (GB) | 1991-02-07 | — | — | WO | disclosed |
| EP-0409575-A1 | Antiviral pyrimidine nucleosides | THE UNIVERSITY OF BIRMINGHAM (GB) | 1991-01-23 | — | — | EP | disclosed |
| US-4689321-A | CYTOLYSIS, ANTITUMOR, ANTICARCINOGENIC | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1987-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | DPYD 250/4885 |
| US-20190255194-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | DPYD 369/4885 |
| US-20240165267-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | DPYD 250/4885 |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | DPYD 369/4885 |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | DPYD 369/4885 |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | DPYD 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.